Akums Drugs Unveils Generic Formulation To Treat Migraine | India Pharma Outlook

Akums Drugs Unveils Generic Formulation To Treat Migraine

India Pharma Outlook Team | Saturday, 06 January 2024

 India Pharma Outlook Team

Akums Drugs & Pharmaceuticals Ltd., a contract manufacturing pharmaceutical firm, announced the launch of the Lasmiditan tablet, which is used to treat migraines. The Drug Controller General of India (DCGI) and the United States Food and Drug Administration (USFDA) have both approved this drug.

It is the generic formulation of Eli Lilly’s REYVOW which is indicated for treatment of acute migraine. Migraine, a chronic neurovascular disorder affecting millions globally, is characterised by recurrent, severe headaches accompanied by nausea and sensitivity to light and sound, as per economic times.

Headache disorders, including migraines and tension-type headaches, were shown to be the most common neurological illnesses in India, impacting an astounding 488 million people.

The International Headache Society (IHS) defines migraine criteria, which include particular features and related symptoms reported in at least five attacks. There are two basic varieties of migraine: migraine without aura and migraine with aura, with the latter comprising focal neurological symptoms before or following the headache.

“Migraine poses a significant global impact. According to a 2019 report, headache disorders, encompassing migraine and tension-type headaches, emerged as the most widespread neurological conditions in India, impacting a staggering 488 million individuals. Despite this substantial prevalence and the resulting disability, migraine awareness among patients remains inadequate. Compounded by frequent misdiagnosis as other headache disorders, these factors contribute to an increased burden associated with migraine. In light of this, Akums aims to provide a solution for managing this condition with the introduction of the Lasmiditan tablet,” Sanjeev Jain, Joint Managing Director, Akums Drugs & Pharmaceuticals Ltd., said

© 2024 India Pharma Outlook. All Rights Reserved.